$CL

Colgate-Palmolive Q2 2026 slides: strong results fuel raised guidance

Colgate-Palmolive (NYSE:CL) reported Q2 2026 results on July 31. Net sales rose 4.9% to $5.36B and organic sales grew 2.4%. Base EPS increased 8% and free cash flow rose 18% YoY to $1.5B YTD. The company raised 2026 guidance, including flat gross margin outlook and higher EPS growth, and projected $350M to $550M pre-tax charges for its 2030 program.

Original reporting
Published Jul 31, 2026, 2:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CL
Bullish
medium confidence
Mentioned
$CL
Relevance
9/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$CLBullishHigh
01

Why it matters

The key tradable update is the raised full-year guidance plus an improved gross margin outlook, supported by stronger free cash flow and base EPS growth, which should shift expectations for FY earnings power.

02

Market read

A same-day earnings and guidance update with explicit margin and EPS direction changes is a direct catalyst for CL’s valuation and positioning.

03

What to watch

The guidance includes impacts from exiting private label pet food; traders may want to separate core organic momentum from divestiture effects when assessing sustainability.

Relevance 9/10Novelty 9/10Timing: reported Q2 2026 earnings and raised full-year guidance today (July 31, 2026)

Background

Colgate-Palmolive delivered Q2 2026 results amid a challenging consumer environment and is executing its 2030 strategy with increased brand investment and a supply-chain/productivity program.

Company-level read

Ticker impact

$CLBullishMedium confidence
Context

Colgate-Palmolive reported Q2 results with net sales up 4.9% and raised full-year guidance, including a higher 2026 gross margin outlook.

Expected impact

Likely positive bias for CL over the next days as traders reprice FY earnings and margin trajectory.

Evidence & confidence

The article discloses multiple forward-looking changes (raised guidance, flat vs prior decline in gross margin, double-digit GAAP EPS growth) tied to the same earnings release, which is typically a direct driver of repricing.

Market effects

Signals resilience in consumer staples demand and supports the view that brand investment and productivity can offset input cost and tariff pressures.

Highlights Europe oral-care share gains (elmex, toothpaste share) which may reinforce regional competitive positioning for oral care.

Global consumer products growth and margin management narrative may influence broader staples sentiment around pricing power and advertising intensity.

Counterpoint

Higher advertising and transformation charges could pressure margins later, so the raised outlook may prove optimistic if input costs or tariffs re-accelerate.

Key entities

  • Colgate-Palmolive Company

    Reported Q2 2026 results and raised full-year guidance, including a higher 2026 gross profit margin outlook.

  • Noel Wallace

    CEO who emphasized increased advertising investment and execution against the 2030 strategy.

Related articles

$CLMed

Colgate-Palmolive Reaffirms Sales Forecast On Weak Demand

Colgate-Palmolive reaffirmed its annual net sales forecast despite a quarterly rise, citing weak North America demand. In the quarter ended June 30, net sales rose 4.9% to $5.36 billion and adjusted EPS was 99 cents. North America organic sales fell 3%, with volumes down 3.9%. The company expects 2026 adjusted earnings growth in mid-single digits and warned tariffs could offset refunds.

$CLMed

Colgate-Palmolive: Base Business EPS Increases 8% As Gross Margin Expands 140 Basis Points

Colgate-Palmolive reported Q2 2026 Base Business diluted EPS up 8% to $0.99 from $0.92, driven by 140 bps gross-margin expansion to 61.5% and higher organic sales. Reported diluted EPS fell 5% to $0.86 due to $129m pretax charges tied to its Strategic Growth and Productivity Program. Net sales rose 4.9% to $5.36b. Full-year organic outlook 1% to 4%; Base Business EPS expected mid-single-digit growth.

$CLMed

Colgate-Palmolive Q2 Earnings Call Highlights

Colgate-Palmolive (NYSE:CL) CFO Stan Sutula said Q2 material costs were slightly below expectations due to higher raw-material costs offset by tariff refunds, with no meaningful additional refunds expected. Management now expects full-year gross margin roughly flat, and warned second-half raw-material and tariff costs will be higher. It plans elevated ad spending and North America share recovery; Hill’s organic sales rose 4% excluding discontinued private-label.

$CLMed

Colgate-Palmolive Lifts FY26 Adj. Earnings View, Despite Weak Q2 Profit; Stock Down

Colgate-Palmolive reported Q2 net earnings of $693 million, down from $743 million a year earlier, with EPS falling to $0.86 from $0.91. Net sales rose to $5.361 billion. The company confirmed FY2026 outlook and raised Base Business EPS growth to mid-single-digit from low- to mid-single-digit, and expects gross margin roughly flat. Shares were down about 2.78% premarket.

$CLMed

Colgate-Palmolive reaffirms annual sales forecast on weak North America demand

Amazon shares rally as cloud growth surges and spending outlook climbs July 31 (Reuters) - Colgate-Palmolive on Friday reaffirmed its annual sales forecast even after posting a quarterly rise as the toothpaste maker continues to grapple with muted demand in North America, sending its shares down 2.5%. Higher food and fuel prices tied to the Middle East conflict have hit lower-income shoppers hard, making it harder for U.S.